Clover Health (NASDAQ: CLOV) CFO’s tax sale covers RSU vesting
Clover Health's Interim CFO, Joseph Clay, sold 17,775 shares of Class A Common Stock at a weighted average price of $4.39 per share on August 17, 2026. This transaction was a non-discretionary "sell to cover" to satisfy tax obligations related to the vesting of 6.25% of his restricted stock units (RSUs). After the sale, Clay directly holds 1,249,526 shares, and his remaining RSUs will continue to vest quarterly through February 2028.
Clover Health interim CFO Thornton sells $78,032 in shares
Joseph Clay Thornton, interim CFO of Clover Health Investments, sold 17,775 shares of the company's Class A Common Stock for $78,032. These sales were not discretionary but rather "sell to cover" transactions to meet tax withholding obligations from vesting restricted stock units (RSUs). Following the transactions, Thornton beneficially owns 1,249,526 shares.
Clover Health (NASDAQ: CLOV) notes $21K 10b5-1 sale by Thornton
Clover Health Investments Corp. (NASDAQ: CLOV) filed a Form 144, indicating a planned transaction involving 16,942 Class A shares linked to restricted stock units granted on August 16, 2026. The filing also disclosed a prior 10b5-1 Plan Sale by Joseph Clay Thornton on July 15, 2026, where 4,630 Class A shares were sold for $21,622.10. The shares for the planned transaction are held through Morgan Stanley Smith Barney LLC.
Clover Health Interim CFO Joseph Clay Thornton Awarded 54,347 RSUs with Four-Year Vesting
Clover Health's Interim CFO, Joseph Clay Thornton, was granted 54,347 Restricted Stock Units (RSUs) of Class A Common Stock. These RSUs, valued at $0, will vest over a four-year period, with 25% vesting on August 12, 2027, and the remainder in quarterly installments, fully vesting by August 12, 2030. This grant increases Thornton's direct beneficial ownership to 1,267,301 shares of Class A Common Stock, contingent upon his continued service.
Clover Health CEO Andrew Toy sells $408,260 in stock By Investing.com
Clover Health CEO Andrew Toy sold 87,798 shares of the company's Class A Common Stock for approximately $408,260. This "sell to cover" transaction was not discretionary but mandated to fulfill tax withholding obligations tied to previously granted restricted stock units. Following this, Mr. Toy beneficially owns over 9.4 million shares.
Clover Health CEO Andrew Toy sells $408,260 in stock
Clover Health CEO Andrew Toy sold 87,798 shares of Class A Common Stock for approximately $408,260. These shares were sold to cover tax withholding obligations from vested restricted stock units, not as discretionary trades. Following the sale, Toy still beneficially owns over 9.4 million shares of Clover Health.
CLOV (Nasdaq: CLOV) discloses planned 85,704-share sale by Andrew Toy
Clover Health Investments, Corp. (Nasdaq: CLOV) has disclosed a planned sale of 85,704 shares of Class A common stock by Andrew Toy through Morgan Stanley Smith Barney LLC, valued at approximately $391,667.28. These shares originate from Restricted Stock Units acquired as compensation on August 8, 2026, with the sale targeting around August 10, 2026. The filing also details previous Rule 10b5-1 plan sales by Andrew Toy on July 1 and July 15, 2026.
Clover Health (CLOV) CEO Andrew Toy sells 87,798 shares for tax withholding
Clover Health CEO Andrew Toy sold 87,798 shares of Class A Common Stock for $408K on August 10, 2026, at a weighted average price of $4.65 per share. This sale was non-discretionary and conducted solely to cover tax withholding obligations associated with the final vesting of restricted stock units. Following this transaction, Toy directly holds 9,459,316 shares of Class A Common Stock.
Clover Health Investments Corp. Class A Revenue Breakdown – MUN:7QD
Clover Health Investments Corp. (MUN:7QD) generated €1.64 billion in revenue last year, primarily from its Insurance segment. All of this revenue, €1.64 billion, originated from the United States, indicating the company's strong focus on the US market in the life and health insurance sector.
Clover Health Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach involving Clover Health Investments, Corp. dba Clover Health. The breach, which was detected on July 8, 2020, and disclosed to the SEC on July 4, 2026, exposed sensitive personally identifiable and protected health information. Individuals affected by the breach may be entitled to compensation and are encouraged to submit a claim for review.
Clover Health Investments Corp. Class A Revenue Breakdown – LS:A2QJXX
Clover Health Investments Corp. Class A (A2QJXX) generated 1.64 billion EUR in revenue last year, primarily from its Insurance segment. This represents an increase from 1.32 billion EUR in the previous year. The entire revenue was generated in the United States.
Clover Health CEO Jamie Reynoso sells $21,920 in CLOV stock By Investing.com
Clover Health's Medicare Advantage CEO, Jamie L. Reynoso, sold 4,839 shares of CLOV stock for $21,920, at a weighted average price of $4.53 per share, according to a Rule 10b5-1 trading plan. This transaction occurred after Clover Health shares surged 73% in six months, and the company recently reported mixed Q1 2026 earnings but had its Medicare star rating upgraded to 4.5 stars. Despite the stock appearing slightly overvalued, Reynoso still holds over 2.8 million shares.
Clover Health CEO, Medicare Advantage Jamie L. Reynoso disposes of 4,839 shares for $21,920.67
Jamie L. Reynoso, CEO of Clover Health Medicare Advantage, sold 4,839 Class A common shares on July 17, 2026, for a total of $21,920.67 at a price of $4.53 per share. Following this transaction, Reynoso's direct stake in Clover Health fell to 2.81 million shares. This information was generated by AI from an original filing by Clover Health Investments Corp. with the SEC.
Clover Health Investments (CLOV) insider sells 4,839 shares under 10b5-1
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), sold 4,839 shares of Class A Common Stock on July 17, 2026. The shares were sold at a weighted average price of $4.53 per share, ranging from $4.35 to $4.63, as part of a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following this transaction, Reynoso directly holds 2,814,640 shares of CLOV.
Clover Health (CLOV) interim CFO sells 4,630 shares to cover taxes
Clover Health's interim CFO, Joseph Clay, sold 4,630 shares of Class A Common Stock on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations related to the vesting of 6.25% of his restricted stock units. Following this transaction, Clay directly holds 1,212,954 shares.
Clover Health CEO Andrew Toy sells $292,860 in shares
Clover Health CEO Andrew Toy sold 62,711 shares of Class A Common Stock for approximately $292,860 on July 15, 2026. This sale was non-discretionary, made to cover tax withholding obligations associated with the vesting of restricted stock units. Despite the sale, Toy still directly owns over 9.5 million shares, and the company is predicted to become profitable this year after a significant Medicare star rating upgrade.
Clover Health: Counterpart Health CEO Wai sells $113,084 in stock.
Conrad Wai, CEO of Counterpart Health at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 24,215 shares of the company’s Class A Common Stock for $113,084. This sale was a "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units and not a discretionary trade. The company recently reported mixed Q1 2026 earnings but received a Medicare star rating upgrade to 4.5 stars.
Clover Health (CLOV) CEO sells 62,711 shares for RSU tax withholding
Clover Health Investments CEO Andrew Toy sold 62,711 Class A shares at a weighted average price of $4.67 per share. This mandatory "sell to cover" transaction was executed to fulfill tax withholding obligations tied to the vesting of 6.25% of his restricted stock units (RSUs), which were originally granted on October 15, 2024. After this non-discretionary sale, Toy directly holds 9,547,114 shares, with remaining RSUs vesting quarterly until October 15, 2028.
Clover Health (NASDAQ: CLOV) insider sale covers RSU tax obligations
Clover Health insider Wai Conrad sold 24,215 Class A shares on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations from the vesting of 6.25% of his restricted stock units (RSUs). Following the sale, Conrad holds 1,145,699 direct shares and 1,390,056 indirect shares, with remaining RSUs vesting quarterly until October 2028.
Clover Health Investments (CLOV) legal chief sells shares in tax-cover transaction
Clover Health Investments' Chief Legal Officer, Karen Soares, sold 10,519 shares of Class A common stock at a weighted average price of $4.67 per share on July 15, 2026. This transaction was to cover tax withholding obligations from the vesting of restricted stock units and was not a discretionary trade. After the sale, Soares retains 1,557,222 shares, with remaining RSUs vesting quarterly until October 2028.
Clover Health (CLOV) exec sells 13,119 shares to cover RSU tax withholding
Clover Health Investments, Corp. executive Jamie L. Reynoso sold 13,119 shares of Class A Common Stock on July 15, 2026, at a weighted average price of $4.67 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units (RSUs), not a discretionary trade. Following this transaction, Reynoso's direct holdings amount to 2,819,479 shares.
CLOV (Nasdaq: CLOV) plans Rule 144 sale of 60765 shares
Clover Health Investments, Corp. (Nasdaq: CLOV) has filed a Form 144 notice for the planned sale of 60,765 shares of Class A Common Stock. These shares originate from Restricted Stock Units granted as compensation and are scheduled to be sold on Nasdaq via Morgan Stanley Smith Barney LLC on July 15, 2026. The filing also discloses Andrew Toy's prior 10b5-1 sales of 313,476 Class A shares on July 1, 2026, for total proceeds of $1,667,692.32.
Sale of 12,712 shares planned in CLOV (Nasdaq: CLOV) notice
An affiliate of Clover Health Investments (Nasdaq: CLOV) plans to sell 12,712 Class A common shares, valued at $59,492.16, through Morgan Stanley Smith Barney LLC around July 15, 2026. These shares originated from restricted stock units granted as compensation. The filing also notes previous 10b5-1 sales by Jamie Reynoso in June and July 2026.
CLOV (CLOV) plans sale of 23,463 Class A common shares
Clover Health Investments, Corp. (CLOV) has filed a Form 144 disclosing a planned sale of 23,463 shares of Class A Common Stock with an aggregate market value of $109,806.84 through Morgan Stanley Smith Barney LLC on July 15, 2026. These shares originated from restricted stock units granted as compensation. Over the prior three months, 220,426 Class A shares were sold for $879,499.74 under 10b5-1 Plan Sales for Conrad Wai.
Weekly Recap: Clover Q2 webcast and Counterpart CA ups discharge data, meds
Clover Health (NASDAQ:CLOV) is scheduled to release its Q2 2026 results on August 5, 2026, followed by a webcast. Its unit, Counterpart Health, reported significant improvements for Clover Medicare Advantage members, with CA-enabled PCPs facilitating 33% more hospital discharge information and 11% better post-discharge medication reconciliation.
Clover Health Medicare Advantage CEO sells $11,157 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NASDAQ:CLOV), sold 2,384 shares of the company's Class A Common Stock for a total of $11,157 on July 8, 2026. This transaction was part of a pre-arranged trading plan. Following the sale, Reynoso still holds over 2.8 million shares, and the company's stock has seen significant year-to-date and six-month gains despite a recent weekly decline.
Clover Health (CLOV) Medicare Advantage CEO sells small stake under Rule 10b5-1 plan
Clover Health Investments, Corp. CEO of Medicare Advantage, Jamie L. Reynoso, sold 2,384 shares of Class A Common Stock at $4.68 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, and leaves Reynoso with 2,832,598 shares directly held. The sale amounts to $11,157 and is considered a neutral filing impact with negative sentiment due to it being a sell.
Jamie Reynoso 10b5-1 sales listed in CLOV Form 144 (CLOV)
A recently filed Form 144 for Clover Health Investments, Corp. (CLOV) details multiple 10b5-1 sales by Jamie Reynoso. The filing, dated July 6, 2026, lists sales on March 18, 2026, June 11, 2026, June 15, 2026, and June 17, 2026, along with Restricted Stock Units dated July 3, 2026. This SEC document provides transparency regarding insider stock transactions under a pre-arranged trading plan.
Clover Health (CLOV) exec sells 6,229 shares in mandated tax-withholding trade
Jamie L. Reynoso, CEO of Medicare Advantage for Clover Health (CLOV), sold 6,229 shares of Class A Common Stock at $5.26 per share. This transaction was not a discretionary trade but a "sell to cover" action to meet tax withholding obligations related to the vesting of restricted stock units (RSUs). After the sale, Reynoso still directly holds 2,834,982 shares of the company.
Clover Health Medicare Advantage CEO Reynoso sells $32,764 in stock
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold 6,229 shares of Class A Common Stock for $32,764 on July 6, 2026. This sale was a "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of restricted stock units. Clover Health recently reported mixed Q1 2026 earnings and had its Medicare star rating upgraded to 4.5 Stars following a lawsuit victory.
Clover Health (CLOV) CEO’s 313,476-share sale tied to RSU tax withholding
Clover Health Investments, Corp. (CLOV) CEO Andrew Toy sold 313,476 shares of Class A common stock at $5.32 per share. This sale was explicitly to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and was a non-discretionary "sell to cover" transaction, as mandated by the company's equity incentive plans. Following the sale, Toy directly holds 9,609,825 shares, and the remaining RSUs will continue to vest quarterly through January 1, 2027.
Clover Health CEO Andrew Toy sells $1.67 million in stock By Investing.com
Clover Health CEO Andrew Toy sold 313,476 shares of Class A Common Stock for $1.67 million to cover tax withholding obligations related to vested restricted stock units. This sale was a "sell to cover" transaction and not a discretionary trade. The stock, trading near its 52-week high, appears overvalued according to InvestingPro analysis, despite a recent Medicare star rating upgrade and exceeding revenue expectations in Q1 2026.
Clover Health CEO Andrew Toy sells $1.67 million in stock
Clover Health CEO Andrew Toy sold 313,476 shares of Class A Common Stock for $1.67 million to cover tax obligations related to restricted stock units. This sale was a mandatory "sell to cover" transaction and not discretionary. The company recently reported Q1 2026 revenue of $749.2 million, exceeding analyst expectations, and received an upgrade to a 4.5-star Medicare rating after a favorable court decision.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
This SEC filing details a Form 144 notice of proposed sale of securities for Clover Health Investments, Corp. (CLOV). The filing indicates an individual plans to sell 309,558 shares of Class A Common Stock, acquired through Restricted Stock Units as compensation, with an aggregate market value of $1,668,517.62 on July 1, 2026. The sale will be executed through Morgan Stanley Smith Barney LLC on the Nasdaq exchange.
ETFs Investing in Clover Health Investments Corp. Class A Stocks
This article provides a list of exchange-traded funds (ETFs) that hold Clover Health Investments Corp. Class A stocks. The funds are sorted by market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), and price performance. The information is presented to help investors find accessible opportunities with lower risk.
CLOV SEC Filings - Clover Health Investments Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Clover Health Investments (CLOV) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details recent insider transaction activity, such as share withholdings for tax purposes and stock sales by executives. The platform also offers AI-powered summaries of these documents and tracks key company announcements, like the 2026 outlook presentation.
7QD Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Clover Health Investments Corp. Class A (7QD) stock based on analyst opinions. It details maximum and minimum price estimates, historical price data, earnings information, and financial performance for the company, including revenue and net income. Additionally, it confirms that 7QD does not pay dividends and offers general information about the company's stock on TradingView.
Clover Health Investments Corp. Class A Actuals & Estimates (NASDAQ:CLOV)
This article provides an overview of Clover Health Investments Corp. (NASDAQ: CLOV), detailing its financial actuals and estimates. It covers the company's current stock price, historical highs and lows, market capitalization, and volatility. Additionally, it includes analysts' forecasts, recent earnings, revenue figures, and upcoming earnings report dates.
Clover Health Investments Corp. Class A Actuals & Estimates (BX:CLOV)
This article provides financial actuals and estimates for Clover Health Investments Corp. Class A (CLOV) traded on the BX Swiss exchange. It details analyst price targets, upcoming earnings dates, past earnings and revenue figures, and confirms that CLOV does not pay dividends. The company has 724 employees as of June 26, 2026, and offers guidance on how to buy its stocks.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Jamie Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 2,360 shares of Class A Common Stock worth $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred while Clover Health shares have risen 104% year-to-date and are trading near their 52-week high. The company recently reported mixed Q1 2026 earnings, exceeding revenue expectations but missing on EPS, and received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Clover Health CEO Jamie Reynoso sold 2,360 shares of Class A Common Stock worth $11,280 on June 17, 2026, through a pre-arranged trading plan. This sale occurred after the company's shares surged 104% year-to-date and were near their 52-week high, with InvestingPro analysis indicating the stock is overvalued. Despite this, Clover Health recently reported Q1 2026 revenue exceeding expectations and received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock
Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 2,360 shares of Class A Common Stock for a total of $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred amidst a 104% year-to-date surge in Clover Health shares, leading to an InvestingPro analysis indicating the stock might be overvalued. The sale follows mixed Q1 2026 earnings for Clover Health and an upgraded Medicare star rating to 4.5 after a favorable court ruling.
Clover Health (CLOV) executive sells 2,360 shares in 10b5-1 plan
Clover Health Investments executive Jamie L. Reynoso, CEO of Medicare Advantage, sold 2,360 shares of Class A common stock at a weighted average price of $4.78 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. Following the transaction, Reynoso directly holds 2,841,211 Clover Health shares, indicating the sale represents a very small portion of her total stake.
Clover Health CEO Jamie Reynoso sells $11,280 in class A stock By Investing.com
Clover Health CEO Jamie Reynoso sold 2,360 shares of Class A Common Stock for $11,280 on June 17, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while Clover Health shares have surged 104% year-to-date and are near their 52-week high. The company recently reported mixed Q1 2026 earnings but received an upgraded Medicare star rating to 4.5 following a favorable court ruling.
Clover Health VP of finance Oldakowski sells $58,815 in stock
Joseph Frank Oldakowski, VP of Finance at Clover Health, sold 12,102 shares of Class A Common Stock for $58,815 on June 16, 2026. This transaction was a "sell to cover" to fulfill tax obligations for vesting restricted stock units (RSUs) and was not a discretionary trade. The sale occurred while Clover Health shares trade near their 52-week high, and the stock is considered overvalued by InvestingPro analysis despite a recent upgrade to a 4.5-star Medicare rating and mixed Q1 2026 earnings.
Clover Health VP of finance Oldakowski sells $58,815 in stock By Investing.com
Joseph Frank Oldakowski, VP of Finance at Clover Health, sold 12,102 shares worth $58,815 to cover tax obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary and occurred as Clover Health's stock is up 110% year-to-date, trading near its 52-week high. The company recently reported mixed Q1 2026 earnings, but achieved a significant upgrade to a 4.5-Star Medicare rating following a favorable court ruling.
Clover Health VP of finance Oldakowski sells $58,815 in stock
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments Corp., sold 12,102 shares totaling $58,815 to cover tax withholding obligations for restricted stock units. This "sell to cover" transaction was not a discretionary trade, and Oldakowski still holds 299,067 shares. The sale comes as Clover Health's stock shows significant year-to-date returns and the company recently reported mixed Q1 2026 earnings but received a major upgrade in its Medicare star rating.
Clover Health (CLOV) finance VP sells 12,102 shares in tax-related RSU transaction
Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health, sold 12,102 shares of Class A Common Stock for $4.86 per share to cover tax withholding obligations related to the vesting of restricted stock units. This "sell to cover" transaction was mandatory and not a discretionary trade. Following the sale, Oldakowski directly holds 299,067 shares.
[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing
Clover Health Investments, Corp. filed a Form 144 on June 16, 2026, reporting the sale of 14,155 shares of Class A Common Stock. This transaction is related to the vesting of restricted stock units and is a routine resale notice under Rule 144. The filing indicates a neutral impact and sentiment, primarily outlining compliance elements for the sale of these compensation-related shares on Nasdaq.
Clover Health CEO Jamie Reynoso sells $29,273 in company stock By Investing.com
Clover Health CEO Jamie Reynoso sold 6,350 shares of the company's Class A Common Stock for $29,273 to cover tax withholding obligations related to restricted stock unit vesting. Following the sale, Reynoso directly owns 2,843,571 shares. Despite the stock trading near its 52-week high and delivering a 105% year-to-date return, InvestingPro analysis suggests it is overvalued, though the company recently reported strong Q1 2026 revenue and an upgraded Medicare star rating.
